Suggested remit - To appraise the clinical and cost effectiveness of baricitinib within its marketing authorisation for treating adults with moderate to severe atopic dermatitis.
 
Status In progress
Process STA 2018
ID number 1622

Provisional Schedule

Committee meeting: 1 10 December 2020
Expected publication 03 March 2021

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Consultees

Companies sponsors Eli Lilly (baricitinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups The National Eczema Society
Professional groups British Association of Dermatologists
  Royal College of Physicians

Commentators

Associated public health groups None
Comparator companies GlaxoSmithKline (alitretion)
  Novartis Pharmaceuticals (ciclosporin, mycophenolate mofetil)
  Sanofi (dupilumab)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
26 June 2020 In progress. In progress
26 June 2020 Baricitinib for treating moderate to severe atopic dermatitis was due to pause , however the topic will now continue on the original timelines and will no longer pause. The timelines are subject to staff capacity and the ongoing management of the COVID-19 situation and we will continue to review our plans and update our stakeholders accordingly.
13 May 2020 Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
17 April 2020 In progress. In progress
17 April 2020 Invitation to participate
06 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
21 November 2019 - 19 December 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance